Equity Profile

RMD

ResMed Inc.

Health CareHealth Care Equipment$30.3B

Aug6Thu

Pre-Earnings Brief

UpcomingQ4-2026After Close5:00 PM EDT

Company Snapshot

ResMed Inc. is a health care company focused on developing equipment related to sleep apnea and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.

Expected to be around $2.86.

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and maintain competitiveness.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

ResMed Inc. is a health care company focused on developing equipment related to sleep apnea and chronic obstructive pulmonary disease (COPD). As a leader in the health care equipment sector, ResMed plays a crucial role in improving patient outcomes through innovative technology and solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In the last quarter, ResMed reported an EPS of $2.86, exceeding analyst expectations by 2.58%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continued focus on innovation in sleep and respiratory care.
Commitment to expanding international markets.
Enhancing digital health solutions to improve patient engagement.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about ResMed's upcoming earnings report, especially given its consistent history of beating EPS estimates. However, the lack of revenue guidance adds an element of uncertainty.

Bull Case

If ResMed continues its trend of beating EPS estimates and shows strong growth in its core markets, it could lead to a positive reaction from investors.

Bear Case

On the other hand, if the company fails to provide clear revenue guidance or if there are signs of market share erosion, it could lead to a negative response.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.86.

EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue Growth

Not available.

Revenue growth is essential for assessing the company's ability to expand its market presence and maintain competitiveness.

Market Share in Sleep Apnea Devices

Not available.

Understanding market share can provide insights into ResMed's competitive position and growth potential in a key segment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the revenue growth rate be for the sleep apnea segment?

Revenue growth in this key area will be crucial for assessing the company's overall health and future prospects.

Will management provide guidance on international market expansion?

Insights into international strategies could indicate potential for future growth and market share gains.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for ResMed's digital health solutions to drive revenue growth, especially as telehealth continues to gain traction.

Supporting Evidence

ResMed's recent investments in digital health could lead to increased patient engagement and revenue.

The options market is pricing a larger move than historical averages, indicating potential for significant surprises.

Management's commitment to innovation may not be fully reflected in current analyst expectations.

Key Risk

If ResMed's digital health initiatives show significant traction, it could lead to a positive surprise in revenue growth.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on how well ResMed can maintain its competitive edge in a rapidly evolving market.

Bull Confirmed If

A revenue growth rate of over 10% in the sleep apnea segment would confirm the bull case.

Bear Confirmed If

A decline in market share or revenue growth below 5% would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5.12%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations and raises guidance, history suggests the stock could rise by about 0.21% on the first day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement.

Miss

If ResMed misses estimates, history suggests a potential decline of around 0.54% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of digital health solutions.
2Any commentary on competitive pressures in the sleep apnea market.
3Details on international market expansion efforts.
4Insights into cost management strategies.
5Future product launches or innovations planned.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

ResMed Inc. is a health care company focused on developing equipment related to sleep apnea and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.

Expected to be around $2.86.

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and maintain competitiveness.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In the last quarter, ResMed reported an EPS of $2.86, exceeding analyst expectations by 2.58%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continued focus on innovation in sleep and respiratory care.
Commitment to expanding international markets.
Enhancing digital health solutions to improve patient engagement.

Expectations

Wall Street Expectations

Bull Case

If ResMed continues its trend of beating EPS estimates and shows strong growth in its core markets, it could lead to a positive reaction from investors.

Bear Case

On the other hand, if the company fails to provide clear revenue guidance or if there are signs of market share erosion, it could lead to a negative response.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.86.

EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue Growth

Not available.

Revenue growth is essential for assessing the company's ability to expand its market presence and maintain competitiveness.

Market Share in Sleep Apnea Devices

Not available.

Understanding market share can provide insights into ResMed's competitive position and growth potential in a key segment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the revenue growth rate be for the sleep apnea segment?

Revenue growth in this key area will be crucial for assessing the company's overall health and future prospects.

Will management provide guidance on international market expansion?

Insights into international strategies could indicate potential for future growth and market share gains.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for ResMed's digital health solutions to drive revenue growth, especially as telehealth continues to gain traction.

Supporting Evidence

ResMed's recent investments in digital health could lead to increased patient engagement and revenue.

The options market is pricing a larger move than historical averages, indicating potential for significant surprises.

Management's commitment to innovation may not be fully reflected in current analyst expectations.

Key Risk

If ResMed's digital health initiatives show significant traction, it could lead to a positive surprise in revenue growth.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on how well ResMed can maintain its competitive edge in a rapidly evolving market.

Bull Confirmed If

A revenue growth rate of over 10% in the sleep apnea segment would confirm the bull case.

Bear Confirmed If

A decline in market share or revenue growth below 5% would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5.12%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations and raises guidance, history suggests the stock could rise by about 0.21% on the first day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement.

Miss

If ResMed misses estimates, history suggests a potential decline of around 0.54% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of digital health solutions.
2Any commentary on competitive pressures in the sleep apnea market.
3Details on international market expansion efforts.
4Insights into cost management strategies.
5Future product launches or innovations planned.